Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
March, 2026
March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Limited Evidence for Anticoagulation Despite High VTE Risk in Sickle Cell Disease – RPTH
First author of the article: Mosaad Almegren/LinkedIn
Mar 16, 2026, 19:03

Limited Evidence for Anticoagulation Despite High VTE Risk in Sickle Cell Disease – RPTH

RPTH Journal shared on LinkedIn about a recent article by Mosaad Almegren et al, adding:

”What’s the best anticoagulant for venous thrombosis in sickle cell disease?

Patients with sickle cell disease (SCD) face a high risk of venous thromboembolism, yet evidence guiding anticoagulation choice remains limited.

A new RPTH study compared direct oral anticoagulants (DOACs) vs warfarin in adults with SCD experiencing their first VTE.

Here’s the key signal:

  • Similar rates of recurrent thrombosis and major bleeding between DOACs and warfarin.
  • Clinically relevant non-major bleeding was significantly lower with DOACs.

Some context from the cohort:

  • 99 patients with SCD and VTE
  • Pulmonary embolism was the most common event (~65%)
  • Median follow-up ~44 months
  • Most DOAC use involved rivaroxaban or apixaban

Translation:

For patients with SCD and thrombosis, DOACs may offer comparable protection with less bleeding burden.

Big questions for the field:

  • Should DOACs become first-line therapy for VTE in SCD?
  • How long should anticoagulation continue in this high-recurrence population?
  • Do SCD-specific thrombosis mechanisms require tailored anticoagulation strategies?”

Title: Management of venous thrombosis in sickle cell disease: a comparative study on the use of direct oral anticoagulants and warfarin

Authors: Mosaad Almegren, Eysa N. AlSolamy, Rayan A. Qutob, Mohammed M. Alasmari, Ali Aljeraiwi, Noura Aljuwaisri, Turki Abdulaziz Alshuaibi, Faisal Bahammam, Bader Al Rawahi, Hoor Hamed Al Farsi

Read the Full Article on RPTH

Limited Evidence for Anticoagulation Despite High VTE Risk in Sickle Cell Disease - RPTH

Stay updated on all scientific advances with Hemostasis Today.

Ali Aljeraiwi Bader Al Rawahi DOACs DVT Eysa N. AlSolamy Faisal Bahammam Health Hematology Hemostasis Hemostasis News Hemostasis Today Hoor Hamed Al Farsi Medicine Mohammed M. Alasmari Mosaad Almegren Noura Aljuwaisri Rayan A. Qutob rpth SCD Sickle Cell Disease thrombosis Turki Abdulaziz Alshuaibi VTE
NewsFeed